Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 06/11 11:35:27 am
3.988 EUR   +2.55%
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

NOVACYT : AGM results July 2019

06/30/2020 | 04:29am EDT

RESULTS OF ANNUAL GENERAL MEETING

Paris, France and Cambridge, UK-18 July 2019-Novacyt (EURONEXT GROWTH: ALNOV; AIM:

NCYT), an international specialist in clinical diagnostics, today held its Annual General Meeting (AGM), on second convening, following the default of quorum at the first General Meeting dated 19 June 2020, on the same agenda.

In the absence of a quorum for extraordinary resolutions, only ordinary resolutions were voted.

The results of the AGM are set out in the table below, with the Company pleased to announce that all ordinary resolutions proposed to the shareholders were duly passed:

Resolutions

Votes For

Votes Against

Result

Number

%

Number

%

1) Approval of the parent company financial statements for the 2018 financial year

4,803,930

76.7%

1,461,313

23.3%

yes

2) Approval of the consolidated financial statements for the 2018 financial year

6,265,296

100%

0

0%

yes

3) Allocation of the result for the 2018 financial year

6,265,296

100%

0

0%

yes

4) Review of the conventions referred to in article L. 225-38 and following of the French Commercial Code (without the vote of Vatel)

3,734,387

59.6%

2,530,909

41.4%

yes

5) DischargetotheBoardof

Directors

6,265,296

100%

0

0%

yes

6) Authorisation of the Company to buy back its own shares

3,734,027

59.59%

2,531,269

41.41%

yes

7) Determination of directors' fees to be allocated to the members of the Board of Directors

6,264,936

99.99%

360

0.01

yes

8) Powers for formalities

6,265,296

100%

0

0%

yes

Number of participating shareholders (by voting form, proxy or present): 41 shareholders representing 6,265,296 shares.

- End-

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products acrossan extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website:www.novacyt.com

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1223 395472

Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)

Jonathan Senior / Fred Walsh / Ben Maddison +44 (0)20 7610 7600

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång +44 (0) 203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell +44 (0)20 3727 1000brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette +33 (0)147 03 69 47 / +33 (0)147 03 69 51arnaud.decheffontaines@fticonsulting.com/astrid.villette@fticonsulting.com

Disclaimer

Novacyt SA published this content on 30 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2020 08:28:03 UTC


© Publicnow 2020
All news about NOVACYT
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
05/26GLOBAL MARKETS LIVE : Amazon, Volkswagen, AstraZeneca, Aston Martin, Sony...
05/26NOVACYT  : Launch of VersaLab™ Portable
PU
05/26NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of VersaLab™ Portable
BU
05/21NOVACYT  : Government and Covid test supplier Novacyt row over £150m PCR contrac..
AQ
05/21NOVACYT  : DHSC Dispute Update
PU
05/21NOVACYT S.A. ("NOVACYT", THE "COMPAN : DHSC Dispute Update
BU
05/17LONDON STOCK EXCHANGE : Banks, industrial stocks drag FTSE 100 down; Diploma jum..
RE
More news
Financials
Sales 2020 312 M 377 M 377 M
Net income 2020 185 M 224 M 224 M
Net cash 2020 102 M 123 M 123 M
P/E ratio 2020 1,52x
Yield 2020 -
Capitalization 282 M 341 M 341 M
EV / Sales 2020 0,58x
EV / Sales 2021 0,38x
Nbr of Employees 110
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 3,99 €
Spread / Highest target 42,9%
Spread / Average Target 22,9%
Spread / Lowest Target 2,81%
EPS Revisions
Managers and Directors
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT-59.31%341
MODERNA, INC.109.49%87 874
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
LONZA GROUP AG16.32%54 656